Travere Therapeutics (TVTX) Operating Income (2013 - 2026)
Travere Therapeutics (TVTX) posted Operating Income of -$36.9 million for Q1 2026, down 13.84% on a QoQ basis from -$32.4 million in Q4 2025, and up 13.5% year-over-year from -$32.5 million in Q1 2025.
Travere Therapeutics (TVTX) Operating Income (2013 - 2026) Analysis & Trends
Travere Therapeutics' Operating Income history runs 14 years deep, the most recent figure standing at -$36.9 million for Q1 2026.
- Quarterly Operating Income rose 13.5% year-over-year to -$36.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.1 million (up 74.89% YoY) and the FY2025 annual result came in at -$62.8 million, up 80.6% from the prior year.
- Operating Income was -$36.9 million for Q1 2026 at Travere Therapeutics, down from -$32.4 million in the prior quarter.
- Across five years, Operating Income topped out at $24.9 million in Q3 2025 and bottomed at -$139.2 million in Q1 2024.
- A 5-year average of -$66.6 million and a median of -$72.0 million in 2022 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income slumped 160.49% — and 2025, when it surged 144.4%.
- Travere Therapeutics' Operating Income stood at -$86.7 million in 2022, then declined by 8.69% to -$94.2 million in 2023, then surged by 35.55% to -$60.7 million in 2024, then surged by 46.61% to -$32.4 million in 2025, then fell by 13.84% to -$36.9 million in 2026.
- Business Quant data shows TVTX's Operating Income at -$36.9 million in Q1 2026, -$32.4 million in Q4 2025, and $24.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -36.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.92 Mn |
| Dec 31, 2025 | -32.43 Mn |
| Sep 30, 2025 | 24.93 Mn |
| Jun 30, 2025 | -12.65 Mn |
| Mar 31, 2025 | -42.67 Mn |
| Dec 31, 2024 | -60.74 Mn |
| Sep 30, 2024 | -56.15 Mn |
| Jun 30, 2024 | -67.70 Mn |
| Mar 31, 2024 | -139.24 Mn |
| Dec 31, 2023 | -94.23 Mn |
| Sep 30, 2023 | -92.59 Mn |
| Jun 30, 2023 | -103.95 Mn |
| Mar 31, 2023 | -97.37 Mn |
| Dec 31, 2022 | -86.70 Mn |
| Sep 30, 2022 | -82.60 Mn |
| Jun 30, 2022 | -78.53 Mn |
| Mar 31, 2022 | -71.98 Mn |
| Dec 31, 2021 | -84.85 Mn |
| Sep 30, 2021 | -31.71 Mn |
| Jun 30, 2021 | -35.32 Mn |